Share-based Payment Arrangement, Expense of Evofem Biosciences, Inc. from 31 Dec 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Evofem Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Sep 2025.
  • Evofem Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $23,000, a 89% decline year-over-year.
  • Evofem Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $312,000, a 66% decline year-over-year.
  • Evofem Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $847,000, a 29% decline from 2023.
  • Evofem Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,189,000, a 64% decline from 2022.
  • Evofem Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,313,000, a 63% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Evofem Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $312,000 $23,000 -$180,000 -89% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $492,000 $31,000 -$188,000 -86% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $680,000 $70,000 -$167,000 -70% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $847,000 $188,000 -$58,000 -24% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $905,000 $203,000 -$55,000 -21% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $960,000 $219,000 -$49,000 -18% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,009,000 $237,000 -$180,000 -43% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $1,189,000 $246,000 +$62,000 +34% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $1,127,000 $258,000 -$723,000 -74% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,850,000 $268,000 -$813,000 -75% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $2,663,000 $417,000 -$650,000 -61% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $3,313,000 $184,000 -$1,166,000 -86% 01 Oct 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
Q3 2022 $4,479,000 $981,000 -$110,000 -10% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $4,589,000 $1,081,000 -$1,912,000 -64% 01 Apr 2022 30 Jun 2022 10-Q 12 Aug 2022 2022 Q2
Q1 2022 $6,501,000 $1,067,000 -$2,397,000 -69% 01 Jan 2022 31 Mar 2022 10-Q 16 Jun 2023 2023 Q1
Q4 2021 $8,898,000 $1,350,000 -$11,347,000 -89% 01 Oct 2021 31 Dec 2021 10-K 27 Apr 2023 2022 FY
Q3 2021 $20,245,000 $1,091,000 -$546,000 -33% 01 Jul 2021 30 Sep 2021 10-Q 06 Jan 2023 2022 Q3
Q2 2021 $20,791,000 $2,993,000 -$3,041,000 -50% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $23,832,000 $3,464,000 +$63,000 +1.9% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $23,769,000 $12,697,000 +$10,858,000 +590% 01 Oct 2020 31 Dec 2020 10-K 04 Mar 2021 2020 FY
Q3 2020 $12,911,000 $1,637,000 -$626,000 -28% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $13,537,000 $6,034,000 +$3,519,000 +140% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $10,018,000 $3,401,000 +$1,439,000 +73% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $8,579,000 $1,839,000 +$83,000 +4.7% 01 Oct 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
Q3 2019 $8,496,000 $2,263,000 -$2,472,000 -52% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $10,968,000 $2,515,000 -$8,148,000 -76% 01 Apr 2019 30 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $19,116,000 $1,962,000 +$1,274,000 +185% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $17,842,000 $1,756,000 +$1,542,000 +721% 01 Oct 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $16,300,000 $4,735,000 +$4,519,000 +2092% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $11,781,000 $10,663,000 +$10,451,000 +4930% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $1,330,000 $688,000 +$469,000 +214% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $861,000 $214,000 -$246,619 -54% 01 Oct 2017 31 Dec 2017 10-K 01 Mar 2019 2018 FY
Q3 2017 $1,107,619 $216,000 +$132,982 +160% 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $974,637 $212,000 +$39,324 +23% 01 Apr 2017 30 Jun 2017 10-Q 02 Aug 2018 2018 Q2
Q1 2017 $935,313 $219,000 -$495,687 -69% 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1
Q4 2016 $1,431,000 $460,619 +$117,852 +34% 01 Oct 2016 31 Dec 2016 8-K/A 06 Apr 2018
Q3 2016 $1,313,148 $83,018 -$282,968 -77% 01 Jul 2016 30 Sep 2016 10-Q 08 Nov 2017 2017 Q3
Q2 2016 $1,596,116 $172,676 -$204,266 -54% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017 2017 Q2
Q1 2016 $1,800,382 $714,687 +$415,601 +139% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q4 2015 $1,384,781 $342,767 +$86,255 +34% 01 Oct 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
Q3 2015 $1,298,526 $365,986 +$228,011 +165% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q2 2015 $1,070,515 $376,942 +$256,560 +213% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2016 2016 Q2
Q1 2015 $813,955 $299,086 +$201,003 +205% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q4 2014 $612,952 $256,512 01 Oct 2014 31 Dec 2014 10-K 23 Mar 2017 2016 FY
Q3 2014 $137,975 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2015 2015 Q3
Q2 2014 $120,382 01 Apr 2014 30 Jun 2014 10-Q 13 Aug 2015 2015 Q2
Q1 2014 $98,083 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1

Evofem Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $847,000 -$342,000 -29% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $1,189,000 -$2,124,000 -64% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $3,313,000 -$5,585,000 -63% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $8,898,000 -$3,799,000 -30% 01 Jan 2021 31 Dec 2021 10-K 27 Apr 2023 2022 FY
2020 $12,697,000 +$4,118,000 +48% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $8,579,000 -$9,263,000 -52% 01 Jan 2019 31 Dec 2019 10-K 04 Mar 2021 2020 FY
2018 $17,842,000 +$16,981,000 +1972% 01 Jan 2018 31 Dec 2018 10-K 12 Mar 2020 2019 FY
2017 $861,000 -$570,000 -40% 01 Jan 2017 31 Dec 2017 10-K 01 Mar 2019 2018 FY
2016 $1,431,000 +$46,219 +3.3% 01 Jan 2016 31 Dec 2016 8-K/A 06 Apr 2018
2015 $1,384,781 +$771,829 +126% 01 Jan 2015 31 Dec 2015 10-K 26 Feb 2018 2017 FY
2014 $612,952 +$532,465 +662% 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2017 2016 FY
2013 $80,487 01 Jan 2013 31 Dec 2013 10-K 29 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.